Study Aims to Demystify the Immune Toxicity Triggered by Osimertinib-ICI Co-Treatment

Study aims to demystify the immune toxicity triggered by osimertinib-ICI co-treatment

Non-small cell lung cancer (NSCLC) accounts for the majority of lung cancer cases and remains a leading cause of cancer mortality worldwide.

EGFR Inhibitor-Linked Cytokine Storms: Study Uncovers the Trigger

In a recent study, researchers have uncovered the biological trigger behind the dangerous immune-related adverse events (irAEs) that occur when the epidermal growth factor receptor (EGFR) inhibitor osimertinib is combined with immune checkpoint inhibitors (ICIs). Using a preclinical mouse model, the team found that this drug duo activates the IL-6/JAK/STAT3 signaling pathway in liver macrophages, unleashing a cytokine storm-like inflammatory resp